quick overview

product name atosiban acetate;
cas no. 90779-69-4;
sequence mpa-d-tyr(et)-ile-thr-asn-cys-pro-orn-gly-nh2(cyclic1-6);
molecular formula c43h67n11o12s2;
molar mass 994.199 g/mol;
purity ≥98%;
impurity ≤0.5% ;
storage temperature 2-8℃;
packing size 1g/bottle, 10g/bottle,50g/bottle or at customers reqirement.

atosiban acetate can postpone its imminent premature birth.

mechanism of action: atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (votra). atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. as a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of ca2+ from the extracellular space through voltage gated channels. in addition, atosiban suppresses oxytocin-mediated release of pge and pgf from the decidua.

originator company: ferring pharmaceuticals

dosage for formulation: 7.5mg/ml

generic api process in our company: atosiban acetate is one of our main peptide projects, related documents will be submitted to the international fda.